Asian Pacific Journal of Cancer Prevention最新文献

{"title":"High Proportion of Cytomegalovirus DNA from Tissue Samples of Non Small Cell Lung Carcinoma in Persahabatan Hospital National Respiratory Center, Indonesia.","authors":"Ibrahim Nur Insan Putra Dharmawan, Jamal Zaini, Irandi Putra Pratomo, Eylin Rahardjo, Hana Khairina Putri Faisal, Dicky Soehardiman, Erlang Samoedro, Triya Damayanti, Diah Handayani, Fanny Fachrucha, Dimas Ramadhian Noor, Sita Laksmi Andarini","doi":"10.31557/APJCP.2025.26.6.1987","DOIUrl":"10.31557/APJCP.2025.26.6.1987","url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus (CMV) is a virus with high seroprevalence in general population. Recent evidence shows that CMV is linked to various types of cancer, including lung cancer. This study aims to determine the relationship between CMV and non-small cell lung carcinoma (NSCLC). Data from this study will be useful for further research in elucidating the link between CMV and lung cancer.</p><p><strong>Method: </strong>This research was an observational study using a cross-sectional method to determine the proportion of CMV DNA in NSCLC tissue samples. Formalin-fixed paraffin-embedded (FFPE) tissue samples were taken from archival at Persahabatan Hospital on 2017-2023. The detection of CMV was carried out using polymerase chain reaction (PCR) and electrophoresis. Accompanying data was taken from medical records.</p><p><strong>Results: </strong>A total of 87 tissue samples from 87 different subjects were included in this study. Most of the research subjects were male smokers, had a heavy Brinkman index with an average age of 59.1 years. The proportion of CMV DNA detected in FFPE samples was 21%. The proportion of CMV DNA was higher in tissue samples with positive EGFR mutations although not statistically significant. The proportion of CMV DNA was not related to smoking status, Brinkman index, tissue sampling method, and NSCLC subtype.</p><p><strong>Conclusion: </strong>High proportion of cytomegalovirus DNA were detected in NSCLC FFPE samples in Indonesia. The proportion of CMV DNA was higher in NSCLC with EGFR mutations.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"1987-1995"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Seeking Behaviour among Cancer Patients with the aid of Geographic Information System: A Mixed-Methods Study from Western India.","authors":"Garima Singh, Pankaja Raghav, Neeti Rustagi","doi":"10.31557/APJCP.2025.26.6.2205","DOIUrl":"10.31557/APJCP.2025.26.6.2205","url":null,"abstract":"<p><strong>Background and objective: </strong>Cancer prognosis depends on early diagnosis and treatment and awareness, beliefs, accessibility, and affordability of health services. Delays in patients seeking health care increase mortality risk. This study has been undertaken in rural Jodhpur (Rajasthan, Western India) to determine the health-seeking behaviour related to common cancers and the factors affecting them.</p><p><strong>Methodology: </strong>A community-based mixed-methods study was conducted in randomly chosen one-third of the Mandore block of Jodhpur villages. Data was collected from individuals diagnosed with cancer/their relatives. In-depth interviews (IDI) were conducted with the frontline workers, cancer survivors, and their caregivers. A geographic information system (GIS) was also used to depict healthcare facilities accessed by cancer patients.</p><p><strong>Results: </strong>A total of 146 participants (diagnosed with cancer) were included in the study. About one-third (34.2%) preferred alternative medicine along with allopathic medicine. The behaviour of changing hospitals frequently was depicted mostly by patients suffering from primary brain tumours (62.5%). Forty-five (31%) participants did not continue their treatment after initiation. From the content analysis of IDI, major factors for delays in health-seeking were misconceptions, superstitions, stigmatisation, financial burden, miscommunication from doctors, no proper referral mechanism, and unfelt need to visit healthcare. None of the participants were aware of the screening services provided and the benefits of screening services. Availability of initial treatment at peripheral centres and training activities for frontline workers and teachers were the major recommendations to improve cancer prevention and control.  Conclusions: Alternative medicine usage was common among cancer patients. Leaving treatment in between was also observed among one-third of the participants. Misconceptions, superstitions, stigmatisation, and financial burden were major factors enlisted for health-seeking delays.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"2205-2213"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Awareness about Cervical Cancer and HPV Vaccine among Undergraduate College Students in Purba Barddhaman District, West Bengal: A Cross-Sectional Study","authors":"Mohini Datta, Sima Roy, Sulagna Das, Pranita Taraphdar, Subhendu Bhuin","doi":"10.31557/APJCP.2025.26.6.2185","DOIUrl":"10.31557/APJCP.2025.26.6.2185","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is a leading cause of mortality among women worldwide. Human Papillomavirus (HPV) plays a definite role in its causation. This study was conducted to assess the level of awareness about cervical cancer and HPV vaccine among urban and rural undergraduate college students in Purba Barddhaman District, West Bengal.</p><p><strong>Methods: </strong>The study was conducted among 420 undergraduate students in two co-educational colleges, one urban and one rural. The data was collected using pre-designed pre-tested open-ended questionnaire and analysed using SPSS (version 23.0). A Chi square test and multiple logistic regression analysis was done to assess the association between variables of interest.</p><p><strong>Result: </strong>Majority of the study subjects,53.8%, were males from urban college and females,52.8%, from rural college and the mean age was 20.09±2.53 and 19.91±2.24 years in urban and rural college respectively. Regarding the knowledge of cervical cancer, only 33.3% from urban and 28.9% from rural college had heard about cervical cancer and 19.5% from urban and 16.1% from rural college had knowledge about its prevention. Regarding HPV infection, 21.3% from urban and 23.3% from rural college had heard about HPV with 13.8% from urban and 12.7% from rural college had heard about the HPV vaccine. Multiple logistic regression analysis revealed that gender retained its statistical significance with risk factors (p=0.007), signs and symptoms (p=0.007) and modes of prevention (p=0.012) of cervical cancer in urban college. In rural college gender was statistically significant with risk factors (p=0.019) and mother's occupation was statistically significant with risk factors (p=0.011) and signs and symptoms (p=0.004) of cervical cancer.</p><p><strong>Conclusion: </strong>Only one-third of the study population had knowledge about cervical cancer and HPV vaccine. Generation of widespread awareness through community participation, mass media involvement and health education is need of the hour.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"2185-2195"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Lenvatinib Versus Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.","authors":"Ni Putu Sri Indrani Remitha, Ni Putu Rista Pradnya Dewi, I Komang Chandra Yogananda, I Gede Aswin Parisya Sasmana, I Komang Wira Ananta Kusuma, I Gede Putu Supadmanaba, Dwijo Anargha Sindhughosa, I Ketut Mariadi","doi":"10.31557/APJCP.2025.26.6.1943","DOIUrl":"10.31557/APJCP.2025.26.6.1943","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) was the third leading cause of cancer-related deaths in the world. Current global treatment recommendations suggest lenvatinib and sorafenib have been approved to treat unresectable HCC. Studies comparing lenvatinib versus sorafenib for unresectable HCC have shown conflicting results and no structured review has yet evaluated its efficacy and safety. This article aims to estimate the efficacy of lenvatinib and sorafenib in patients with unresectable HCC.</p><p><strong>Methods: </strong>This research was conducted using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) strategy. Literature searches were conducted through PubMed, ScienceDirect, Google Scholar, Cochrane Library, SpringerLink, and Ebsco. After quality assessment using the Newcastle-Ottawa Scale (NOS) and Cochrane Risk-of-bias, also data extraction, Review Manager 5.4 and RStudio 2024.04.1 software were used for analysis of overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR).</p><p><strong>Results: </strong>A total of 9 studies were included, comprising 3,821 samples. All studies were retrospective studies. Our meta-analysis showed that OS and PFS in patients receiving lenvatinib were significantly better than patients receiving sorafenib with a protective hazard ratio (HR) of 0.70 (95%CI: 0.57-0.87, p=0.001) and 0.65 (95%CI: 0.54-0.78; p < 0.00001) respectively. Moreover, in the viral patients group, lenvatinib showed similar OS compared with sorafenib (HR=1.02; 95%CI: 0.77-1.36, p=0.87). Lenvatinib exhibited better ORR (OR = 7.87; 95%CI: 2.02-30.75; p = 0.003) and DCR (OR = 1.99; 95%CI: 1.53-2.60; p < 0.00001) compared with sorafenib.</p><p><strong>Conclusion: </strong>Lenvatinib provided significant benefits in OS, PFS, ORR, and DCR compared to sorafenib in patients with unresectable HCC.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"1943-1952"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Breaking Barriers in Cancer Screening: Understanding Participant Dropout in Breast and Cervical Programs in Morocco.","authors":"Fareeda Brohi","doi":"10.31557/APJCP.2025.26.6.1873","DOIUrl":"10.31557/APJCP.2025.26.6.1873","url":null,"abstract":"","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"1873-1874"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Introduction of the HPV Vaccine among Young Girls to Reduce the Long-Term Risk of Cervical Cancer in Eswatini: Programmatic Decision and Roll Out.","authors":"Teluleko N Maseko, Xolilesile Dlamini, Velephi Okello, Rejoice Nkambule, Joyce M Tsoka-Gwegweni, Jean Paul M Milambo","doi":"10.31557/APJCP.2025.26.6.1891","DOIUrl":"10.31557/APJCP.2025.26.6.1891","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is a significant public health concern in Eswatini. In June 2023, the Eswatini government launched a national school based vaccination program aimed at administering two doses of the human papillomavirus (HPV) vaccine to adolescent girls, with the second dose administered six months after the first.</p><p><strong>Objective: </strong>This study seeks to assess the feasibility of school based HPV vaccination introduction campaign for prevention of cervical cancer among women in the Kingdom of Eswatini in Africa. The lessons learned, and challenges faced during the implementation of the national HPV vaccination program designed to prevent HPV infection are documented to improve HPV vaccination campaign in Africa.</p><p><strong>Methods: </strong>The review study details the planning and execution of the HPV vaccination initiative within Eswatini's school based campaign, targeting 82,400 girls aged 9-14 years from 12 to 23 June 2023 schooldays.</p><p><strong>Results: </strong>The national goal was to vaccinate 82,400 girls. The campaign achieved a national coverage rate of 55.9%, with 46,512 girls successfully vaccinated. The Manzini region recorded the highest coverage at 60.1%, while the Shiselweni region had the lowest at 48.2%.</p><p><strong>Conclusions: </strong>The introduction of the large-scale HPV vaccination campaign in schools proved successful. However, challenges such as misconceptions about eligibility criteria and misinformation persisted, impacting vaccine uptake and coverage. Continued efforts in community mobilization, public education on eligibility, and integration with healthcare services are essential for sustaining the program. Strengthening partnerships and mobilizing resources will also be critical for its long-term success.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"1891-1897"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor Suppressor miRNA-based Signatures in Triple Negative Breast Cancer: A Study Based on Big Data Analysis of Gene Expression Omnibus (GEO) Datasets and Its Validation.","authors":"Kavitha Unnikrishnan, Sivakumar Krishnankutty Chandrika, Ram Mohan Ram Kumar, Priya Srinivas","doi":"10.31557/APJCP.2025.26.6.2087","DOIUrl":"10.31557/APJCP.2025.26.6.2087","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence highlights the therapeutic potential of microRNAs (miRNAs) in cancer, positioning them as key molecular tools in personalized medicine. In this study, we aim to identify miRNAs as novel indicators of poor prognosis in Triple Negative Breast Cancer (TNBC) patients and to explore their potential therapeutic options for TNBC.</p><p><strong>Materials and methods: </strong>Potent tumor suppressor miRNAs were obtained from four available datasets (GSE38167, GSE40049, GSE86278, GSE154255) of the Gene Expression Omnibus database comprising a total of 94 TNBC-positive and 40 normal tissue samples were analyzed using DESeq2 software. Further, TargetScan was used to predict the targets of differentially downregulated miRNAs and the functional and pathway enrichment analyses were performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) bioinformatics tool. The data obtained were validated by quantitative real-time PCR (qRT-PCR). Finally, survival analysis was performed in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort to check the impact of these miRNAs in TNBC patients.</p><p><strong>Results: </strong>Differential expression analysis revealed that 110 miRNAs were upregulated and 243 miRNAs were downregulated in TNBC samples compared to the normal breast tissue samples. The top five downregulated miRNAs were miR-204, miR-6068, miR-139, miR-26a and miR-215. The Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology analysis showed that these miRNAs are involved in various hallmarks of cancer. Further validation using qRT-PCR analysis showed that miR-204, miR-139, and miR-26a were significantly downregulated in TNBC cell lines, MDA-MB-231, MDA-MB-468 and HCC1937 compared to non-tumorigenic cell line, MCF 10A. Kaplan-Meier analysis showed that the survival rate of patients with low miR-204 expression was significantly lower compared to the miR-204 upregulated group.</p><p><strong>Conclusion: </strong>miR-204 can be a potential therapeutic molecule in TNBC. Strategies aimed at restoring the expression of miR-204 through miRNA replacement therapies could offer novel therapeutic approaches for TNBC patients.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"2087-2095"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the Genetic Associations with Epigenetic Age Acceleration in Childhood Cancer Survivors: Insights from GWAS Studies.","authors":"Maryam Yazdanparast, Rezvan Nezameslami, Alireza Nezameslami, Bahareh Mehdikhani, Hossein Neamatzadeh","doi":"10.31557/APJCP.2025.26.6.1871","DOIUrl":"10.31557/APJCP.2025.26.6.1871","url":null,"abstract":"","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"1871-1872"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Catastrophic Health Expenditure and its Associated Factors among Adult Cancer Patients in a Teaching Hospital in East Coast of Malaysia.","authors":"Muhammad Abdul Hafiz Kamarul Zaman, Surianti Sukeri, Norazlina Mat Nawi, Suhailah Badaruddin, Mohd Arif Saifudin Sulong, Aienuddin Husairi Hussain, Mohd Shafizol Mohamad Zuki, Azlan Husin","doi":"10.31557/APJCP.2025.26.6.2035","DOIUrl":"10.31557/APJCP.2025.26.6.2035","url":null,"abstract":"<p><strong>Objective: </strong>To determine the proportion of Catastrophic Health Expenditure (CHE) and its associated factors among adult cancer patients in a teaching hospital in the East Coast of Malaysia.</p><p><strong>Methodology: </strong>A cross-sectional study was conducted at a teaching hospital involving 209 randomly-selected adult cancer patients who were diagnosed for at least one year. Guided interviews were conducted using a questionnaire. The Budget Share method i.e. out-of-pocket (OOP) health expenses exceeding 10% of household income was used to define CHE. To prevent overestimation of CHE, non-medical spending were excluded.</p><p><strong>Results: </strong>The study revealed that 15.3% of patients experienced CHE. Significant factors associated with CHE were ethnicity, education level, ownership of guarantee letter (GL), and employment status. Non-Malay patients had 6.63 times the odds of experiencing CHE compared to Malay patients (p-value=0.013, 95% CI: 1.49, 29.57). Patients with primary school qualification had 9.56 times the odds of experiencing CHE compared to those with tertiary education (p-value=0.005, 95% CI: 2.01,45.57). Patients without GL were 4.81 times more likely to experience CHE than those with GL (p-value=0.008, 95% CI: 1.51, 15.34). Households where the head was unemployed had 6.55 times the odds of experiencing CHE compared to those with employed heads (p-value=0.014, 95% CI: 1.46,29.35).</p><p><strong>Conclusion: </strong>The proportion of CHE is low, nevertheless the burden of non-medical spending and indirect costs, remains concerning. Financial aid may be considered on vulnerable groups such as non-Malay patients, those with lower education levels, individuals without GL, and unemployed head of households.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"2035-2042"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti- Cancer Potential of Diosgenin, a Steroidal Saponin, against Human Oral Cancer Cells.","authors":"Uma Dutta, Sonali Dey, Monikongkona Boruah, Bethsebie Lalduhsaki Sailo, Bhaigyaroti Muchahary, Ajaikumar B Kunnumakkara","doi":"10.31557/APJCP.2025.26.6.2049","DOIUrl":"10.31557/APJCP.2025.26.6.2049","url":null,"abstract":"<p><strong>Objective: </strong>Oral squamous cell carcinoma (OSCC), affecting the lip and oral cavity, is one of the most prevalent cancers worldwide with the highest morbidity rate in the North-Eastern region of India. The current treatment options including surgery and chemotherapy are plagued by adverse side-effects and emergence of chemo-resistance, particularly against drugs like cisplatin and 5-fluorouracil. The present study focuses on demonstrating the effects of diosgenin, a naturally occurring steroidal saponin, on the survival, proliferation, and migration of OSCC cells in vitro.</p><p><strong>Methods: </strong>Preliminary in vitro screening of diosgenin in OSCC cells was performed using MTT, colony formation, cell cycle arrest, PI-FACS, live/dead, and wound-healing assays. In addition, the potential of diosgenin in regulating the expression of critical proteins involved in OSCC was evaluated using western blot analysis.</p><p><strong>Result: </strong>The present study shows that diosgenin exhibited selective anti-proliferative activity on OSCC cell lines SAS and HSC3 compared to normal kidney cell line HEK-293T. In addition, it enhances the chemosensitivity of SAS cells to cisplatin and 5-FU. This compound also displayed anti-clonogenic, cell cycle arrest, cytotoxic, and anti-migratory effects on SAS cells in a dose-dependent manner. Further, diosgenin regulated the expressions of COX-2, CXCR-4, VEGF, TWIST-1, p-AKT, and AKT, which are critical proteins for the development and progression of OSCC.</p><p><strong>Conclusion: </strong>These findings support the therapeutic potential of diosgenin, thereby opening a new avenue for oral cancer therapy. Nonetheless, the data needs to be further validated in in vivo and clinical settings.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"2049-2059"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}